Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Zalicus third quarter revenue increases to $2.4 million

Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.

2 Nov 2011

Glyphosine can prevent development of type 1 diabetes

Researchers at the University of Colorado School of Medicine have found a specific molecule that can prevent the development of type 1 diabetes in mice and has a similar effect on human cells from diabetic patients.

2 Nov 2011

Marathon recovery tips

More than 40,000 runners have spent the past several months training for the ING New York City Marathon. Once they have completed the race and achieved their goals, there are measures they can take to facilitate recovery, decrease post-race discomfort and return to running without injury. Eating immediately after the marathon, icing sore muscles, and having a gentle massage are only a few of the tips that Michael Silverman, PT, MSPT, physical therapist from the Rehabilitation Department at Hospital for Special Surgery in New York, offers runners who cross the finish line.

2 Nov 2011

Regular Yoga eases chronic back pain: Study

A new study found that those with chronic back pain might benefit from regular yoga. Three months of weekly yoga classes eased back pain more than the usual course of care — an informative back pain booklet said researchers. Even a year later, patients with chronic back pain who had participated in yoga classes reported less pain than those who hadn't been assigned the classes.

1 Nov 2011

Rigel reports net loss of $17.9 million for third quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011.

1 Nov 2011

Scientists identify genetic mutation that causes rare childhood disease

An international collaboration of scientists, including researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health, has identified a genetic mutation that causes a rare childhood disease characterized predominantly by inflammation and fat loss.

1 Nov 2011

Researchers discover biomarker for earlier diagnosis of MS

Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called "blurring", may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, such as multiple sclerosis.

1 Nov 2011

European Congress on Osteoporosis & Osteoarthritis to be held March 21-24

The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.

1 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

Free computer application accurately models human motion

There are 640 muscles in the human body, or maybe it is 639. Or maybe it is 850. Or 656. It all depends on whom you ask. In any case, it is a lot. Stanford bioengineer Scott Delp knows; he has programmed almost every one into his latest work, OpenSim, a software application that helps medical professionals and bioengineers study, diagnose and correct abnormalities in how people move.

29 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

IFPA event to raise awareness of psoriasis on Oct. 29

Psoriasis can be a truly devastating disease, as it not only affects your health but can also have a severe impact on how you live your life. Many people with psoriasis experience social stigmatization and discrimination on a more or less daily basis, in a wide range of settings; at school, at work, at the gym, in public bath houses.

28 Oct 2011

RA drug reduces kidney cyst growth in ADPKD mouse model

Scientists at UC Santa Barbara have discovered that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses.

28 Oct 2011

Insight into role of cytokines in autoimmune diseases

Cytokines, a varied group of signaling chemicals in the body, have been described as the software that runs the immune system, but when that software malfunctions, dysregulation of the immune system can result in debilitating autoimmune diseases such as lupus, arthritis, and diabetes. Leading experts in the field of cytokine research present their most up-to-date findings and unique perspectives on the role of cytokines in autoimmune diseases in a special issue of Journal of Interferon & Cytokine Research, a peer-reviewed publication of Mary Ann Liebert, Inc.

28 Oct 2011

Beneficial intestinal bacteria can activate immune cells and trigger MS

Multiple sclerosis is caused by a combination of genetic and environmental factors. For a long time, pathogens were believed to be such external influences. According to scientists from the Max Planck Institute of Neurobiology in Martinsried, however, it is apparently not harmful bacteria that trigger multiple sclerosis, but beneficial ones - specifically, the natural intestinal flora, which every human being needs for digestion.

28 Oct 2011

La Jolla Institute becomes 5th participant in novel stem cell research collaboration

The La Jolla Institute for Allergy & Immunology has become the fifth organization in the prestigious Sanford Consortium for Regenerative Medicine, joining colleagues from the Salk Institute for Biological Studies, The Scripps Research Institute, University of California, San Diego and the Sanford-Burnham Medical Research Institute in the first-of-its-kind multi-institutional stem cell research collaboration.

28 Oct 2011

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron Pharmaceuticals, Inc. today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago.

28 Oct 2011

NHMRC awards $2 million to investigate new therapies for reversing autoimmune disease

Research being undertaken at the University of Adelaide and Women's and Children's Hospital is providing vital clues into the causes of autoimmune diseases which affect millions of people around the world.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011